title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study",20220802T122759,https://www.benzinga.com/general/biotech/22/08/28308082/biotech-daily-trial-setback-for-eliem-therapeutics-allarity-drops-work-on-cancer-monotherapies-ax,CLLS,0.157483,Neutral,0.03904
Stocks That Hit 52-Week Lows On Friday,20220506T160650,https://www.benzinga.com/markets/options/22/05/27050916/52-weeks-high-and-low-article,CLLS,0.005467,Neutral,-0.012085
Stocks That Hit 52-Week Lows On Monday,20220613T161842,https://www.benzinga.com/markets/options/22/06/27677156/52-weeks-high-and-low-article,CLLS,0.005366,Neutral,-0.007774
71 Biggest Movers From Yesterday,20220520T082731,https://www.benzinga.com/news/22/05/27318002/71-biggest-movers-from-yesterday,CLLS,0.055946,Neutral,0.006819
"Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday - ABVC BioPharma  ( NASDAQ:ABVC ) , Altimmune  ( NASDAQ:ALT ) ",20220926T074323,https://www.benzinga.com/news/22/09/29002223/why-nanovibronix-shares-surged-over-25-here-are-82-biggest-movers-from-friday,CLLS,0.066784,Neutral,-0.128011
Stocks That Hit 52-Week Lows On Friday,20220610T154524,https://www.benzinga.com/markets/options/22/06/27650434/52-weeks-high-and-low-article,CLLS,0.013393,Neutral,0.007266
"Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire",20240318T093600,https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-is-estimated-to-contribute-39-to-the-growth-technavio-302090363.html,CLLS,0.033562,Neutral,0.110176
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",20230925T210100,https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,CLLS,0.037504,Neutral,0.05738
